CTOs on the Move

Oxis International

www.oxis.com

 
Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oxis.com
  • 468 N Camden Dr
    Beverly Hills, CA USA 90210
  • Phone: 650.212.2568

Executives

Name Title Contact Details

Similar Companies

FamilyServiceRV

#Mentalhealth causes invisible wounds. Find strength, hope and how you can help heal others. Family Service of Roanoke Valley. https://t.co/57fyeIBthG

Douglas Laboratories

Douglas Laboratories is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABS Corporation

ABS Corporation is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monticello Drug Company

Monticello Drug Company is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.